Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy.

Abstract	A 6-year-old boy with improving juvenile dermatomyositis (JDM) developed severe and debilitating calcinosis, unresponsive to diltiazem and probenecid. Alendronate produced dramatic improvement within 1 month and by 12 months calcinosis had virtually resolved. The response was followed by bone mineral content measurements.
Authors	Geoffrey R Ambler, Jeffrey Chaitow, Maureen Rogers, David W McDonald, Robert A Ouvrier
Journal	The Journal of rheumatology (J Rheumatol) Vol. 32 Issue 9 Pg. 1837-9 (Sep 2005) ISSN: 0315-162X [Print] Canada
PMID	16142885 (Publication Type: Case Reports, Journal Article)
Chemical References	Prednisone Alendronate Methotrexate
Topics	Alendronate (administration & dosage) Calcinosis (diagnostic imaging, drug therapy, etiology) Child Dermatomyositis (complications, diagnostic imaging, drug therapy) Dose-Response Relationship, Drug Drug Administration Schedule Drug Therapy, Combination Follow-Up Studies Humans Male Methotrexate (administration & dosage) Prednisone (administration & dosage) Radiography Risk Assessment Severity of Illness Index Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!